Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder

Overview

Journal J Clin Psychiatry

Specialty Psychiatry

Date 2023 Apr 19

PMID 37074295

Authors

Zhenhao Shi

Xinyi Li

Kyle M Kampman

Anna Rose Childress

Corinde E Wiers

Daniel D Langleben

Affiliations

Soon will be listed here.

References

Huhn A, Sweeney M, Brooner R, Kidorf M, Tompkins D, Ayaz H . Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients. Neuropsychopharmacology. 2018; 44(4):826-833. PMC: 6372589. DOI: 10.1038/s41386-018-0252-0. View

Latif Z, Saltyte Benth J, Solli K, Opheim A, Kunoe N, Krajci P . Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. JAMA Psychiatry. 2018; 76(2):127-134. PMC: 6439739. DOI: 10.1001/jamapsychiatry.2018.3537. View

Courtney K, Schacht J, Hutchison K, Roche D, Ray L . Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict Biol. 2015; 21(1):3-22. PMC: 4986996. DOI: 10.1111/adb.12314. View

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M . Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. Am J Drug Alcohol Abuse. 2016; 42(5):614-620. PMC: 5156574. DOI: 10.1080/00952990.2016.1197231. View

Zaaijer E, van Dijk L, de Bruin K, Goudriaan A, Lammers L, Koeter M . Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. Psychopharmacology (Berl). 2015; 232(14):2597-607. PMC: 4480848. DOI: 10.1007/s00213-015-3891-4. View

Volkow N, Jones E, Einstein E, Wargo E . Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA Psychiatry. 2018; 76(2):208-216. DOI: 10.1001/jamapsychiatry.2018.3126. View

Jelen L, Stone J, Young A, Mehta M . The opioid system in depression. Neurosci Biobehav Rev. 2022; 140:104800. PMC: 10166717. DOI: 10.1016/j.neubiorev.2022.104800. View

Hesse M . The Beck Depression Inventory in patients undergoing opiate agonist maintenance treatment. Br J Clin Psychol. 2006; 45(Pt 3):417-25. DOI: 10.1348/014466505x68069. View

Krupitsky E, Nunes E, Ling W, Gastfriend D, Memisoglu A, Silverman B . Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013; 108(9):1628-37. DOI: 10.1111/add.12208. View

10.

Langleben D, Ruparel K, Elman I, Loughead J, Busch E, Cornish J . Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients. Addict Biol. 2012; 19(2):262-71. DOI: 10.1111/j.1369-1600.2012.00462.x. View

11.

Moffett L, Radenhausen R . Assessing depression in substance abusers: Beck Depression Inventory and SCL-90R. Addict Behav. 1990; 15(2):179-81. DOI: 10.1016/0306-4603(90)90023-q. View

12.

Dean A, Saunders J, Jones R, Young R, Connor J, Lawford B . Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci. 2006; 31(1):38-45. PMC: 1325065. View

13.

Shi Z, Wang A, Jagannathan K, Fairchild V, OBrien C, Childress A . Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder. J Psychiatry Neurosci. 2018; 43(4):254-261. PMC: 6019353. View

14.

Emery M, Akil H . Endogenous Opioids at the Intersection of Opioid Addiction, Pain, and Depression: The Search for a Precision Medicine Approach. Annu Rev Neurosci. 2020; 43:355-374. PMC: 7646290. DOI: 10.1146/annurev-neuro-110719-095912. View

15.

Na P, Scodes J, Fishman M, Rotrosen J, Nunes E . Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone and Injection Naltrexone. J Clin Psychiatry. 2022; 83(3). DOI: 10.4088/JCP.21m14140. View

16.

Smith S, Nichols T . Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2008; 44(1):83-98. DOI: 10.1016/j.neuroimage.2008.03.061. View

17.

Shi Z, Jagannathan K, Padley J, Wang A, Fairchild V, OBrien C . The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder. Addict Biol. 2020; 26(4):e12977. DOI: 10.1111/adb.12977. View

18.

Havard A, Teesson M, Darke S, Ross J . Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat. 2006; 30(4):355-62. DOI: 10.1016/j.jsat.2006.03.012. View

19.

Rounsaville B, Weissman M, Wilber C, Kleber H . Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982; 39(2):151-6. DOI: 10.1001/archpsyc.1982.04290020021004. View

20.

Krupitsky E, Nunes E, Ling W, Illeperuma A, Gastfriend D, Silverman B . Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377(9776):1506-13. DOI: 10.1016/S0140-6736(11)60358-9. View